Angitia Biopharmaceuticals
Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing bispecific antibody therapeutics that simultaneously target sclerostin and DKK1 proteins for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta, and spinal fusion indications.
- Company typePrivate
- Founded2018
- HeadquartersWestlake Village, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Angitia Biopharmaceuticals does
Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing bispecific antibody therapeutics for serious musculoskeletal diseases. Founded in 2018 and headquartered in Woodland Hills, California, with additional operations in China, the company is advancing three drug candidates through clinical development: AGA2118 for postmenopausal osteoporosis (Phase 2 ARTEMIS trial with 379 women enrolled and topline expected in 2027), AGA2115 for osteogenesis imperfecta (Phase 2 IDUN trial, first patient dosed January 2026), and AGA111 for spinal fusion. The company's core technology centers on bispecific antibodies that simultaneously engage sclerostin and Dickkopf-1 (DKK1) proteins, a dual-target architecture positioned to overcome the limitations of single-target therapies such as Amgen's romosozumab. Its website also highlights adjacent musculoskeletal indications including bone metastasis, muscle disorders, and osteoarthritis.
The company is pre-revenue and finances operations entirely through venture capital. Across six disclosed funding rounds since 2020, Angitia has raised approximately $406 million in aggregate, most recently a $130 million Series D in February 2026 co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners, with participation from Bain Capital Life Sciences, Hillhouse, OrbiMed, BlackRock, Wellington Management, RA Capital, and others. A $120 million Series C led by Bain Capital Life Sciences closed in December 2024, following a $46 million Series B led by Morningside in October 2023.
Angitia intends to commercialize its biologic products through traditional pharmaceutical distribution channels — hospital pharmacies, specialty pharmacies, and healthcare providers — upon regulatory approval, targeting postmenopausal women with osteoporosis, osteogenesis imperfecta patients, and patients requiring spinal fusion procedures. The company employs 51–100 staff, is led by founder and CEO Hua Zhu Ke, and added Kevin Li, M.D., Partner at Frazier Life Sciences, to its Board of Directors in connection with the Series D financing.
Angitia Biopharmaceuticals firmographics
Firmographics- Name
- Angitia Biopharmaceuticals
- Legal name
- Angitia Biopharmaceuticals Limited
- Website
- https://angitiabio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing bispecific antibody therapeutics that simultaneously target sclerostin and DKK1 proteins for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta, and spinal fusion indications.
- Ownership category
- akta.pro rank
Angitia Biopharmaceuticals industry classification
Industry- Product category
- Musculoskeletal Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro industry
- Bispecific & Multispecific AntibodiesHealthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
Keywords
Where Angitia Biopharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Westlake Village
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Angitia Biopharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Biopharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue expected from sales of approved biologic therapeutics for musculoskeletal diseases including osteoporosis, osteogenesis imperfecta, and spinal fusion upon successful clinical development and regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Angitia Biopharmaceuticals product offering
Product offeringCore offering
Angitia Biopharmaceuticals is a clinical-stage biotechnology company that discovers and develops biologic therapeutic candidates for serious musculoskeletal diseases. Its pipeline comprises three bispecific antibody drug candidates: AGA2118 for postmenopausal osteoporosis (Phase 2 ARTEMIS trial), AGA2115 for osteogenesis imperfecta (Phase 2 IDUN trial), and AGA111 for spinal fusion. The bispecific antibodies simultaneously target sclerostin and Dickkopf-1 (DKK1) proteins to overcome limitations of single-target bone therapies.
Product overview
Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing a pipeline of bispecific antibody drug candidates for serious musculoskeletal diseases. The company's portfolio includes three clinical-stage candidates: AGA2118 for postmenopausal osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. The bispecific antibodies target both sclerostin and Dickkopf-1 (DKK1) proteins simultaneously to overcome limitations of single-target therapies for bone loss conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- AGA2118 Bispecific antibody drug candidate targeting sclerostin and Dickkopf-1 (DKK1) proteins simultaneously, in development for the treatment of postmenopausal osteoporosis. Currently in Phase 2 (ARTEMIS) trial with enrollment of 379 women completed.
- AGA2115 Bispecific antibody drug candidate in development for the treatment of osteogenesis imperfecta (OI), a serious genetic bone disorder. Currently in Phase 2 (IDUN) trial with first participant dosed in January 2026.
- AGA111
Quantifiable outcome
- Phase 2 trial ARTEMIS enrolled 379 women for AGA2118 in postmenopausal osteoporosis - topline results expected 2027
Companies that use Angitia Biopharmaceuticals
Customer profileSegments3 records
Ideal customer profiles1 record
Angitia Biopharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Angitia Biopharmaceuticals partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
Angitia Biopharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- UCB: UCB is Amgen's co-development and co-promotion partner on romosozumab (Evenity) for osteoporosis. UCB represents a potential strategic acquirer or commercial partner for Angitia given overlapping bone-disease commercial infrastructure outside the US.
- Amgen: Amgen co-developed and markets Evenity (romosozumab), the first approved sclerostin-targeting antibody for postmenopausal osteoporosis. Romosozumab is the most direct competitive analog to Angitia's AGA2118 in mechanism and indication, though it targets only one of the two pathways AGA2118 engages.
- Eli Lilly: Lilly markets Forteo (teriparatide) and Taltz in adjacent bone and inflammation indications, and is one of the dominant incumbent players in metabolic bone disease. Lilly represents the broad incumbent peer and potential strategic acquirer given the size of its bone franchise.
- BridgeBio Pharma: BridgeBio is a clinical-stage rare disease biotech with multiple programs across genetic diseases. While not focused on musculoskeletal indications, BridgeBio is a structural peer in the clinical-stage rare disease and orphan drug space, particularly relevant for valuing Angitia's AGA2115 osteogenesis imperfecta program.
Others
- Genmab: Genmab is a leader in bispecific antibody engineering with its DuoBody platform, used across multiple therapeutic areas. While not a direct competitor in musculoskeletal disease, Genmab is a technology-platform peer whose valuation and partnership economics inform the bispecific antibody space Angitia operates in.
Emerging players
- Ascendis Pharma: Ascendis Pharma develops TransCon PTH (palopegteriparatide) for hypoparathyroidism and is exploring bone-related indications using its TransCon prodrug technology. The company is a peer in late-stage bone therapeutics with a similar clinical-stage, partnership-friendly profile.
- Entera Bio: Entera Bio is developing oral PTH formulations (EB613) for osteoporosis and hypoparathyroidism. While mechanistically distinct from Angitia's bispecific antibodies, Entera is a clinical-stage peer targeting the same postmenopausal osteoporosis market with a differentiated route of administration.
Direct peers
- Mereo BioPharma: Mereo is advancing setrusumab (anti-sclerostin) for osteogenesis imperfecta and other bone disorders, making it a direct competitor to Angitia's AGA2115 in the OI indication. Both companies are clinical-stage with a shared target biology in rare bone disease.
- Ultragenyx Pharmaceutical: Ultragenyx is developing UX143 (setrusumab), an anti-sclerostin antibody for osteogenesis imperfecta — directly competing with Angitia's AGA2115 in the same rare bone disease indication and overlapping mechanism (sclerostin inhibition).
- Radius Health: Radius developed and previously marketed Tymlos (abaloparatide), a parathyroid hormone analog for postmenopausal osteoporosis. Radius is a direct commercial-stage peer in osteoporosis therapeutics and a useful comparator for go-to-market economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Angitia Biopharmaceuticals social profiles
Digital presenceAngitia Biopharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Angitia Biopharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
Angitia Biopharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Angitia Biopharmaceuticals funding detail
Funding detailFunding overview
Funding rounds6 records
Investors23 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Angitia Biopharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Angitia Biopharmaceuticals
What does Angitia Biopharmaceuticals do?
Angitia Biopharmaceuticals is a clinical-stage biotechnology company that discovers and develops biologic therapeutic candidates for serious musculoskeletal diseases. Its pipeline comprises three bispecific antibody drug candidates: AGA2118 for postmenopausal osteoporosis (Phase 2 ARTEMIS trial), AGA2115 for osteogenesis imperfecta (Phase 2 IDUN trial), and AGA111 for spinal fusion. The bispecific antibodies simultaneously target sclerostin and Dickkopf-1 (DKK1) proteins to overcome limitations of single-target bone therapies.
Is Angitia Biopharmaceuticals a public or private company?
Angitia Biopharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Angitia Biopharmaceuticals founded?
Angitia Biopharmaceuticals was founded in 2018. It employs 51 to 100 people.
Where is Angitia Biopharmaceuticals based?
Angitia Biopharmaceuticals is headquartered in Westlake Village, United States, in the North America region.
How does Angitia Biopharmaceuticals make money?
One revenue line is on record: biopharmaceutical Product Sales.
Who are Angitia Biopharmaceuticals's main competitors?
Broad incumbents on record are UCB, Amgen, Eli Lilly and BridgeBio Pharma. Genmab is listed as an others. Emerging players are Ascendis Pharma and Entera Bio. Direct peers are Mereo BioPharma, Ultragenyx Pharmaceutical and Radius Health.
Does Angitia Biopharmaceuticals have an API?
No public API is recorded for Angitia Biopharmaceuticals.
What industry is Angitia Biopharmaceuticals in?
Angitia Biopharmaceuticals's product category is Musculoskeletal Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.